A recent report showed reduced colitis severity by treatment with the macrolide 7-O-succinyl macrolactin A (SMA), which was mediated in part through inhibiting TNF-induced PI3K, AKT, mTOR and p70S6 kinase phosphorylation [100]. Here, TNF is linked to colitis.